Gurpreet Singh, MD
Ophthalmology · Houston, TXNPI 1669475919
Payments from drug & device makers
Across 222 payments — averaging $32.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$1K
- AbbVie$952
- Sun Pharmaceutical Industries Inc.$934
- Zimmer Biomet$828
- Glaukos Corporation$454
- Bausch & Lomb, A Division Of Bausch Health US, LLC$401
- plus $2K from 26 others
What the payments were for
- Consulting fees$1,30018%
- Travel & lodging$75010%
- Food & beverage$5,20572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 6 | $1,396 |
| AbbVie(2 entities) | 37 | $952 |
| Sun Pharmaceutical Industries Inc. | 42 | $934 |
| Zimmer Biomet | 5 | $828 |
| Glaukos Corporation | 12 | $454 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $401 |
| Alcon | 14 | $379 |
| Ocular Therapeutix, Inc. | 14 | $348 |
| Oyster Point Pharma, Inc. | 6 | $141 |
| Novartis | 7 | $132 |
| Bausch & Lomb Americas Inc. | 6 | $127 |
| Tarsus Pharmaceuticals, Inc. | 4 | $117 |
| Eyevance Pharmaceuticals LLC | 6 | $115 |
| Rxsight Inc | 4 | $107 |
| Biotissue Holdings Inc. | 5 | $103 |
| Merck | 1 | $98 |
| Carl Zeiss Meditec USA, Inc. | 1 | $66 |
| Amgen | 3 | $66 |
| Harrow Eye, LLC | 2 | $61 |
| Merz North America, Inc. | 3 | $59 |
| Sight Sciences, Inc. | 3 | $47 |
| Thea Pharma Inc. | 2 | $47 |
| Aerie Pharmaceuticals, Inc. | 2 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 2 | $33 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $32 |
| Insmed, Inc. | 1 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $26 |
| NEW World Medical,inc. | 2 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $21 |
| Dompe US, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$1,300
- ROSA$715
- XEN GLAUCOMA TREATMENT SYSTEM$150
- Clareon$126
- DEXTENZA$125
- Photrexa Viscous and Photrexa$102
How this compares
$7,254 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 106 | $135,761 |
| LumiganBimatoprost | 153 | $67,984 |
| Cyclosporine | 76 | $53,885 |
| XiidraLifitegrast | 37 | $47,315 |
| Prednisolone Acetate | 877 | $35,501 |
| VyzultaLatanoprostene Bunod | 43 | $24,151 |
| Fluorometholone | 242 | $19,537 |
| RhopressaNetarsudil Mesylate | 47 | $18,371 |
| MoxifloxacinMoxifloxacin Hcl | 809 | $16,649 |
| CombiganBrimonidine Tartrate/Timolol | 48 | $14,573 |
| CequaCyclosporine | 11 | $14,370 |
| ZirganGanciclovir | 23 | $13,853 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 65 | $13,602 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $13,199 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 45 | $11,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $952 | $218,318307 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Zirgan | $127 | $85,318103 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $39 | $31,57168 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $934 | $14,37011 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $401 | $13,14853 claims |
| AlconSimbrinza | $379 | $11,07545 claims |
| Harrow Eye, LLCVevye | $61 | $7,53311 claims |
| Thea Pharma Inc.Iyuzeh | $47 | $3,67211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.